ASBP
****Sponsored by Interactive Offers, LLC.
The Company has assembled a world class team and is led by a CEO who has achieved more than $1B market caps on not one, but two previous companies!
Aspire's most advanced pharmaceutical program is a high-dose sublingual aspirin formulation positioned for use in acute settings such as a suspected heart attack or stroke Aspire
Biopharma Announces $5.0 Million Share Repurchase Program
READ THE INVESTOR PRESENTATION HERE
________________________
Hello Everyone,
We have witnessed some real movers and shakers over the past week or so. The overall markets are at all time highs despite an ongoing war and the small cap market is absolutely loaded with opportunity for those paying attention. We have something urgent for you to research as today's session gets going.
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) is a biopharma company with a patent-pending drug delivery platform designed to enable rapid sublingual absorption — delivering drugs directly into the bloodstream through buccal tissue, bypassing the digestive tract and first-pass liver metabolism entirely.
Sublingual drug delivery is one of those areas where the science and the business case point in the same direction, which doesn't always happen in biopharma.
From a purely medical standpoint, the mouth is one of the most efficient entry points into the bloodstream. When a drug dissolves under the tongue compared to a pill, which has to survive stomach acid, travel through the small intestine, get absorbed, and then pass through the liver before it ever reaches its target it is far more efficient. That liver step — first-pass metabolism — is where a significant portion of many drugs get broken down and rendered inactive before they even have a chance to work. Sublingual delivery skips all of that.
For a company like ASBP, that matters enormously for a few reasons.
Reformulation opportunity. Existing drugs that work but have absorption or side effect problems can potentially be reformulated sublingually without starting from scratch on safety and efficacy data. That's a faster, cheaper path to a product than developing a new molecule entirely.
Better patient outcomes drive adoption. Faster onset is not just a selling point — for drugs like emergency medications, pain management, anxiety treatment, or cardiac drugs, minutes matter. A drug that works in two minutes versus thirty is a meaningfully different product, and physicians and patients notice that.
Easier administration opens new markets. Patients who can't swallow pills — children, elderly patients, people with dysphagia, or someone in a medical emergency — represent a large underserved population. A company with a platform that reaches those patients has access to demand that oral solid drugs simply can't serve.
Platform economics. This is the biggest business angle. A company that owns a proprietary sublingual delivery mechanism isn't just selling one drug — it's sitting on a platform that can potentially be licensed to other drug makers or applied across multiple compounds. That transforms the company from a single-product bet into something with recurring, scalable value. Every new drug that gets reformulated using the platform is another revenue stream.
IP protection. A patent-pending delivery mechanism creates a moat that's separate from the underlying drug itself. Even when a molecule goes generic, a proprietary delivery method can maintain pricing power and exclusivity.
The bottom line is that sublingual delivery isn't a gimmick — it solves real pharmacological problems that have existed for decades. For a company that owns the platform rather than just a single drug, the upside is significant: faster development timelines, broader patient reach, licensing potential, and defensible intellectual property all in one.
The platform offers four core advantages over traditional drug delivery. First, it is significantly faster acting, with drugs entering the bloodstream in as little as one to two minutes. Second, by bypassing the digestive tract, less of the drug is lost to digestion, and skipping the GI tract can reduce irritation and adverse reactions. Third, avoiding a first pass through the liver means the drug isn't metabolized before it reaches the bloodstream — so more of the dose actually does its job. Fourth, the delivery method is easier to use: a small amount of pleasant-tasting powder or granules works for patients who struggle with pills or capsules, and can even be administered to someone who is unconscious.
ASBP just reversed effective May 11, drastically reducing shares outstanding from approximately 36,329,490 to approximately 1,210,983, a move the company says is aimed at supporting its projected expansion. This is GREAT news for anybody looking at the company right now. There is just over 5 million outstanding.
Sublingual Aspirin as a Proof of Concept
Aspire's most advanced pharmaceutical program is a high-dose sublingual aspirin formulation positioned for use in acute settings such as a suspected heart attack or stroke.
The market opportunity for sublingual aspirin is significant, with the combined opioid and non-opioid markets currently estimated at approximately US$80 billion, expected to grow to US$100 billion over the next five years.
A Pipeline Of Opportunity
Beyond aspirin, Aspire is positioning its platform across multiple therapeutic categories, including:
Rather than relying on the success of a single novel drug, Aspire is attempting to build a system that can be applied across multiple existing therapies.
Aspire Biopharma Clinical Pipeline
- Sublingual Aspirin: Aspire's lead candidate, a fast-acting high-dose sublingual aspirin for acute heart attacks, showed it could inhibit platelet aggregation in under two minutes-4 to 5 times faster than chewed tablets.
- FDA Milestones: The company plans to file a New Drug Application (NDA) via the 505(b)(2) pathway near the end of 2026 for its lead aspirin candidate.
- Expanded Pipeline: Formulation and development underway for generic sublingual versions of anti-anxiety drug (generic Xanax®), anti-nausea drug (generic Zofran®), anti-platelet drug (generic Plavix®), as well as others
- Intellectual Property: The company now has patents filed and pending on eleven different drugs and supplements, including the filing of an omnibus patent application with the U.S. Patent and Trademark Office for its sublingual delivery technology for several key drug classes.
An Expanding Retail Footprint: The Pre-Workout Market
This market is currently estimated at approximately US$20 billion and is expected to reach approximately US$28 billion by 2030.
On March 10, Aspire Biopharma announced that its subsidiary, Buzz Bomb Caffeine Company, is expanding its retail footprint with the launch of the BUZZ BOMB™ Convenience Store Pack.
Buzz Bomb Expansion - The Pre-Workout Market Is Booming — and Ripe for Disruption
The global pre-workout supplement market is on a strong growth trajectory, expected to reach $27.97 billion by 2030 at a compound annual growth rate of 5.9%. The tailwinds are hard to ignore. Gym memberships are rising, consumers are more focused than ever on performance and recovery, and the category is expanding well beyond its traditional base of hardcore gym-goers — women, Gen Z, and casual exercisers are all entering the market in meaningful numbers. Add in the explosive growth of ready-to-drink formats and demand for cleaner, more natural formulations, and you have a category with serious momentum.
The problem is that the market is also saturated. Hundreds of products compete for shelf space and attention, and the vast majority of them share the same fundamental limitation: they come in powder form, require mixing with water, and take 20 to 30 minutes to digest before the user feels anything. That delay creates real friction — it complicates timing, makes caffeine management harder, and forces athletes and exercisers to plan around their supplement instead of the other way around.
Consumer research backs this up. When people are asked what they actually want from a pre-workout product, immediacy, ease of use, and the ability to take it when they need it — not 30 minutes before they think they might need it — consistently rank at the top of the list.
That's exactly where BUZZ BOMB comes in. With a delivery mechanism designed to work significantly faster than anything currently on the market, BUZZ BOMB isn't just another option in a crowded category — it's a fundamentally different approach to what a pre-workout product can be. That kind of differentiation is what drives rapid customer conversion, brand loyalty, and long-term market share in a space where most products are essentially interchangeable.
- Retail Partnerships:
o Partnered with TruLife Distribution for nationwide sales, distribution, and merchandising
o Signed agreements with Interwest Brokerage to expand retail footprint across the Intermountain West
Financial Milestones In 2026
- Capital Injection: The company secured US$21 million in private placement financing in its February 2026 and April 2026 preferred stock offerings.
- Exchange Compliance: Aspire regained compliance with Nasdaq's minimum stockholders' equity requirement in April 2026 and has received confirmation from Nasdaq.
- Potentially Transformative Acquisition: On April 15, 2026, Aspire entered a Binding Letter of Intent to acquire DCS, a global automotive supplier, for approximately US$30 million in cash.
- Commitment Letter: The company secured a Commitment Letter from a leading financial institution of up to US$22.5M to finance the proposed acquisition of
Sublingual Aspirin Product
ASBP’s Sublingual Aspirin Product addresses cardiology emergencies and pain management. It is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin, which has been developed by using the company’s patented formulation, and “trade secret” process.
Benefits of “rapid absorption” aspirin are: to stop heart attack and stroke; allow high dose absorption for pain management, including quick headache relief, post-surgery, cancer pain management, and general pain relief.
In the planned initial launch of its sublingual products, Aspire has focused on the delivery of aspirin, which may be the most studied and accepted analgesic and anti-inflammatory.
Aspirin is over a century old and is traditionally available in several forms, including effervescence, powder, capsule, and tablet. Over 100 years of documented safety and efficacy data is readily available.
Aspirin is also the only drug in history to receive a certified recommendation by the FDA for heart attack, stroke and colon cancer prevention. However, current aspirin applications are limited due to side effects and the gastric tract.
The Company plans to seek FDA 505(b)(2) Fast Track designation for the prescription strength sublingual aspirin. The 505(b)(2) pathway specifically benefits new drugs that are similar to already approved drugs but have slight variations in formulation or administration routes. Aspire can reference the safety and efficacy data of the original innovator drugs–which are already FDA-approved–accelerating the approval process and reducing associated costs.
The Competitive Edge
ASBP’s sublingual aspirin product, which addresses cardiology emergencies and pain management among other impacts, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. Benefits of “rapid absorption” aspirin are to stop heart attack and stroke; allow high-dose absorption for pain management, including quick headache relief, post-surgery, cancer pain management, and general pain relief.
Commercialization and Go-to-Market Strategy
- Launch the sublingual aspirin product initially in the Rx market, followed eventually by an OTC version, with the strategy of creating and preserving greater long-term value.
- Partner with an experienced end-to-end marketing and distribution firm. The company is currently evaluating potential partners.
- Significant Licensing Opportunity.
- Aspire is also developing important non-FDA products with limited regulatory hurdles to come to market sooner, such as a preworkout product and a melatonin-based sleep aid.
Manufacturing
ASBP has entered into a development and manufacturing agreement with a well-known manufacturer–Glatt, based in Ramsey, New Jersey– to produce sufficient quantities of its sublingual drug product for the clinical trials required to obtain FDA approval to market the product and complete clinical trials.
Although the company believes that Glatt is capable of producing the drug product to support the company’s sublingual aspirin development plan, including its planned clinical trials, ASBP also believes there are a number of alternative third-party manufacturers that have similar capabilities and would be capable of providing sufficient quantities of drug product if necessary.
ASBP has entered into a fill-and-finish agreement with a contract manufacturer to convert sublingual aspirin manufactured by Glatt into packaged drug products that can be utilized in clinical trials and stability testing. The fill-and-finish contract manufacturer will package the aspirin product that has been produced by Glatt into a drug product to be used in the company’s upcoming clinical trials. The company believes that both Glatt and the fill-and-finish contract manufacturer are compliant under current good manufacturing practice, or cGMP, requirements and have experience with cGMP inspections of their respective facilities.
- Plans to use the sublingual aspirin manufactured by Glatt to conduct clinical trials to support approval of a section 505(b)(2) New Drug Application (“NDA”). An initial trial will be designed to study the pharmacokinetics of aspirin and its metabolites in blood following sublingual administration of a single dose of each of two different formulations of the Instaprin drug product and a single dose of standard oral aspirin. This initial trial is expected to enroll at least six healthy adult volunteers with each dose separated by a washout period of seven days and will provide information required to (i) select the optimal drug product formulation and (ii) inform the design of a second clinical trial to support FDA approval. The first trial will also demonstrate the relative quickness of Aspire’s sublingual aspirin’s absorption compared to orally administered aspirin tablets. The company plans to design a second clinical trial to demonstrate that sublingual administration of the final selected formulation delivers therapeutic concentrations of drug into the bloodstream, comparable to those of standard oral aspirin, but faster and without gastro-intestinal toxicity associated with oral aspirin. The second trials will also focus on the anti-platelet properties of the sublingual aspirin.
Commercialization
Subject to receiving marketing approvals, ASBP expects to commence commercialization activities by building a focused sales and marketing organization in the United States to sell its products, as well as the creation of a dedicated Medical Affairs team to support commercialization efforts. The company believes that such an organization will be able to address the physicians who are the key specialists in treating the patient populations for which its product candidates are being developed. Outside the United States, it expects to enter into distribution and other marketing arrangements with third parties for any of its product candidates that obtain marketing approval.
ASBP also plans to build a marketing and sales management organization to create and implement marketing strategies for any products that it markets through its own sales organization and to oversee and support its sales force.
NEWS
Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio
May 7, 2026
Aspire Biopharma Announces $5.0 Million Share Repurchase Program
Apr 27, 2026
Apr 20, 2026
Apr 17, 2026
Apr 16, 2026
Apr 15, 2026
Mar 19, 2026
Mar 17, 2026
Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026
Mar 12, 2026
Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack
Mar 10, 2026
MANAGEMENT
Sincerely,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS A PUBLICATION OF ONE22 MEDIA, LLC, HEREIN REFERRED TO AS O22. O22’S REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATIONAL PURPOSES ONLY.O22 IS ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.
O22 HAS BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY A THIRD PARTY, INTERACTIVE OFERS, LLC FOR A ONE DAY ASBP PROFILE ON 5/27/26. O22 HAS BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY A THIRD PARTY, INTERACTIVE OFERS, LLC FOR A ONE DAY ASBP PROFILE ON 3/27/25.
BY SUBSCRIBING TO OR OTHERWISE USING THIS WEBSITE/NEWSLETTER, YOU AGREE TO HOLD O22 AND ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS, DAMAGE, OR INJURY THAT YOU MAY INCUR, MONETARY OR OTHERWISE.
INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. NEVER INVEST IN ANY STOCK FEATURED ON O22’S SITE OR NEWSLETTER UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING O22’S SERVICES, JOINING O22’S SITE OR EMAIL/BLOG LIST, OR FOLLOWING ANY SOCIAL NETWORKING PLATFORMS O22 MAY USE.
PLEASE NOTE WELL: O22 IS NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. O22 IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES AND EXCHANGE COMMISSION, OR FINRA. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED.
THE INFORMATION CONTAINED HEREIN IS BASED ON INFORMATION SUPPLIED BY THE COMPANIES PROFILED, PUBLICLY AVAILABLE INFORMATION, PRESS RELEASES, AND OTHER SOURCES WHICH O22 BELIEVES TO BE RELIABLE, BUT IS NOT GUARANTEED BY O22 AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES PROFILED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER IN DECIDING TO INVEST OR MAKE OTHER FINANCIAL DECISIONS. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. O22 STRONGLY ENCOURAGES READERS AND INVESTORS TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES, INCLUDING BY REVIEWING SEC FILINGS (FORMS 10-Q, 10-K, 8-K, 3, 4, 5, SCHEDULE 13D) AND BY CONSULTING YOUR OWN TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS.
THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT, AND MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEES, EXPECTS, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, MAY, COULD, OR MIGHT. THERE IS NO GUARANTEE THAT PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.